Novo Nordisk A/SNVONYSE
Loading
Operating Income PerformanceStrong
Percentile Rank100
3Y CAGR+20.2%
5Y CAGR+19.1%
Year-over-Year Change
Profit from core business operations before interest and taxes
3Y CAGR
+20.2%/yr
vs +12.2%/yr prior
5Y CAGR
+19.1%/yr
Consistent
Acceleration
+8.0pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.4x
Strong expansion
Streak
7 yr
Consecutive growthStrong
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $129.83B | +1.2% |
| 2024 | $128.34B | +25.1% |
| 2023 | $102.57B | +37.1% |
| 2022 | $74.81B | +27.6% |
| 2021 | $58.64B | +8.3% |
| 2020 | $54.13B | +3.1% |
| 2019 | $52.48B | +11.1% |
| 2018 | $47.25B | -3.5% |
| 2017 | $48.97B | +1.1% |
| 2016 | $48.43B | - |